Description
BMS-986253 is an investigational drug currently being studied in clinical trials, specifically in combination with nivolumab, for certain types of early-stage colon cancer. It is being evaluated in patients with microsatellite instability-high (MSI-H) or microsatellite stable (MSS) tumors. The drug is part of a larger clinical trial (NCT03026140) exploring different combinations of immunotherapy drugs (like ipilimumab, nivolumab, relatlimab) and other agents (like celecoxib) before surgery (neoadjuvant setting). The goal is to see if these combinations can improve outcomes, such as disease-free survival, compared to standard treatments. The trial design has been updated multiple times to include more patients and different treatment arms.
Mechanism of Action
BMS-986253 is an antibody that targets interleukin-8 (IL-8). IL-8 is a protein that can promote tumor growth and spread by attracting certain immune cells and influencing the tumor microenvironment. By blocking IL-8, BMS-986253 aims to potentially inhibit tumor growth and enhance the effectiveness of other immunotherapy drugs like nivolumab.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.